⇚ Regimen VYLOY® with mFOLFOX 6 - for Gastric and GEJ cancer Medical Name VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin), 5-FU and Leucovorin. Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positive Cycles Given 12 Delivery Phases N/A Special Instructions The first dose is given at 800 mg/m2 and subsequent doses are given at 600 mg/m2 every 3 weeks or 400 mg/m2 every 2 weeks. Monitor for hypersensitivity reactions, severe nausea and/or vomiting References Shitara K, et al. Lancet. 2023 - VIEW External References https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00620-7/abstract - VIEW Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration VYLOY® (Zolbetuximab) IV 800 mg/m2 D1 N/A NSS 1000 cc 4-5 hours VYLOY® (Zolbetuximab) IV 400 mg/m2 D1 q14 NSS 500 cc 3-4 hours ELOXATIN® (Oxaliplatin) IV 85 mg/m2 D1 q14 D5W 250 cc 120 minutes 5-Fluorouracil IV 400 mg/m2 D1 q14 IV Bolus none Slow IV Push - over 3 to 5 minutes 5-Fluorouracil - continuous infusion CI 2400 mg/m2 D1 q14 NSS 100 cc 46 hours (ambulatory pump) Leucovorin IV 200 mg/m2 D1 q14 NSS 250 cc 120 minutes